Selective Inhibition of Enzyme Isoforms of Nitric Oxide Synthetase
This discovery provides for drug discovery and design protocols for isoform drugs that target NOS isoforms and reduce NO production.
University of California, Irvine researchers have discovered a method to design and use selective inhibitors against a family of nitric oxide synthetase isoforms that control the production of nitric oxide (NO). X-ray crystallography was utilized to generate isoform specific NOS-inhibitor complexes with unique structural characteristics. An overproduction of NO has been linked to several diseases, conditions and addictions, including: ischemic injury and other brain damage after stroke, migraine headache, Alzheimer's Disease, colitis, tissue damage, inflammation, septic shock and rheumatoid arthritis.
Patent Number: US7056945B1
Application Number: US2003463213A
Inventor: Poulos, Thomas | Li, Huiying | Flinspach, Mack
Priority Date: 14 Jun 2002
Priority Number: US7056945B1
Application Date: 17 Jun 2003
Publication Date: 6 Jun 2006
IPC Current: A61K003140 | A61K003116
US Class: 514428 | 514429 | 514614
Assignee Applicant: The Regents of the University of California
Title: Selective inhibition of neuronal nitric oxide synthase
Usefulness: Selective inhibition of neuronal nitric oxide synthase
Summary: (A) is useful to treat or prevent disorder in human or veterinary patient mediated by neuronal nitric oxide synthase (nNOS) inhibitor (claimed).
Novelty: Composition, useful to treat or prevent disorder in human or veterinary patient mediated by neuronal nitric oxide synthase inhibitor, comprises nitro-aminoimine compounds
Biomedical
Medical Composition
7056945
Tech ID/UC Case 18881/2002-460-0 Related Cases 2002-460-0
USA
